Rombo syndrome

Rombo syndrome is an extremely rare genetic skin disorder characterized by a distinctive combination of dermatological features that typically become apparent in childhood and progress over time. The condition primarily affects the skin, particularly of the face and extremities. Key clinical features include vermiculate atrophoderma (a pattern of small, worm-like depressions in the skin, especially on the cheeks), milia (small white cysts), telangiectasias (dilated small blood vessels visible on the skin surface), acral erythema (redness of the hands and feet), and trichoepitheliomas (benign skin tumors arising from hair follicles). Patients may also develop basal cell carcinomas, typically appearing in adulthood, which represents an important complication requiring long-term dermatological surveillance. The syndrome was first described by Michaëlsson and colleagues in 1981 in a Swedish family. The atrophoderma vermiculatum usually appears in childhood, often between ages 7 and 10, while the cyanotic redness of the lips, hands, and feet may be noted earlier. Trichoepitheliomas and basal cell carcinomas tend to develop later, often in the third or fourth decade of life. The condition shares some clinical overlap with Bazex-Dupré-Christol syndrome, another rare genodermatosis featuring follicular atrophoderma and basal cell carcinomas, but Rombo syndrome is distinguished by the presence of telangiectasias and acral erythema and the absence of hypotrichosis. There is currently no cure for Rombo syndrome. Management is primarily symptomatic and involves regular dermatological monitoring for the early detection and treatment of basal cell carcinomas. Sun protection is strongly recommended to reduce the risk of skin cancer development. Individual skin lesions such as trichoepitheliomas or basal cell carcinomas can be treated with surgical excision, cryotherapy, or other standard dermatological procedures. Genetic counseling is recommended for affected families.

Common questions about Rombo syndrome